Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started
My Medicine

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Breast Cancer Health Center

Font Size

Arimidex Better Than Tamoxifen Long Term

New Option for Some Women With Early Breast Cancer


This means that women taking Arimidex are 18% less likely to suffer a recurrence of their disease compared with women taking tamoxifen, says study head Aman Buzdar, MD, an oncologist at the University of Texas M.D. Anderson Cancer Center in Houston.

"Compared with placebo, tamoxifen reduces the risk of recurrence by about 50%. Compared with tamoxifen, Arimidex reduces that risk another 20%. That's a 70% reduction in relative risk," says Buzdar.

As for side effects, unlike tamoxifen, Arimidex is not associated with an increase in the risk of uterine cancer or dangerous blood clots. But patients taking Arimidex are more susceptible to bone fractures than those taking tamoxifen, an indication that the new drug accelerates bone loss. A bone-building supplement could prevent many aromatase inhibitor-related fractures, Buzdar says.

The bottom line: "Arimidex should be considered a better choice of therapy for postmenopausal women with hormone-sensitive early breast cancer."

Nevertheless, he stressed, the ultimate choice should be the patient's. "I sit down with each woman and explain the options and that there is some risk of a bone-related event. Nine in 10 women will want the newer drug. But some will want the drug that's been around 30 years."

Winer says the new data will be considered when ACOG convenes its annual expert panel on breast cancer treatment in a few months.

"Though the figures don't seem that different from a year ago [when the panel voted to keep tamoxifen as standard therapy], we have four years of experience instead of three. That means something," he said. "But will we change our recommendations? That's up to the whole panel."

In the meantime, Winer agreed. "It all comes down to sitting down with a woman, telling her everything we know about both drugs and making the decision together."

1 | 2

Today on WebMD

Breast Cancer Overview
From self-exams and biopsies to reconstruction, we’ve got you covered.
Dealing with breast cancer
Get answers to your questions.
woman having mammogram
Experts don’t agree on all fronts, but you can be your own advocate.
woman undergoing breast cancer test
Many women worry. But the truth? Most abnormalities aren’t breast cancer.
Breast Cancer Treatments Improving
Resolved To Quit Smoking
Woman getting mammogram
Screening Tests for Women
ovarian cancer overview slideshow
serious woman
what is your cancer risk
10 Ways to Revitalize Slideshow